Kong, Tim http://orcid.org/0000-0002-3240-8989
Laranjeira, Angelo B. A.
Yang, Kangning http://orcid.org/0000-0002-5211-913X
Fisher, Daniel A. C.
Yu, LaYow
Poittevin De La Frégonnière, Laure
Wang, Anthony Z.
Ruzinova, Marianna B.
Fowles, Jared S.
Fulbright, Mary C.
Cox, Maggie J.
Celik, Hamza
Challen, Grant A.
Huang, Sidong http://orcid.org/0000-0002-2838-4726
Oh, Stephen T. http://orcid.org/0000-0002-8564-5400
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (T32HL007088, R01HL147978)
Gouvernement du Canada | Canadian Institutes of Health Research (PJT-156233, PJT-438303)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA91842)
Leukemia and Lymphoma Society
MPN Research Foundation
Article History
Received: 16 November 2021
Accepted: 8 November 2022
First Online: 29 December 2022
Competing interests
: S.T.O. has served as a consultant for Kartos Therapeutics, CTI BioPharma, Celgene–Bristol Myers Squibb, Disc Medicine, Blueprint Medicines, PharmaEssentia, Constellation, Geron, AbbVie, Sierra Oncology and Incyte. G.A.C. has received research funding from Incyte. All other authors disclose no competing interests.